Author: Sasidhar Alluru, B. B. V. Sailaja and Arani Pal

DOI: http://doi.org/10.31788/RJC.2023.1618187

A new series of 1H-naphtho[2,3-d]imidazole-4,9-dione-based 1,2,3-triazole hybrids (10a-10n) were synthesized by the reaction of 1-(prop-2-yn-1-yl)-1H-naphtho[2,3-d]imidazole-4,9-dione with aromatic azides via copper-catalyzed azide-alkyne cycloaddition reactions. All the synthesized compounds are screened for their in vitro anticancer activities against three cancer cell lines namely MCF-7 (breast), HeLa (cervical), and A-549 (lung) using an MTT assay. The results revealed that the compounds 10a,10c,10g, and 10k exhibited promising activity against three cancer cell lines. Especially, compound 10a displayed higher activity against all the cell lines than the standard drug, The molecular docking studies of compounds 10a-10n as EGFR targeting agents were also supported by the observed IC50 data.

Keywords: 1H-naphtho[2,3-d]imidazole-4,9-dione, In vitro Anticancer Activity, Molecular Docking, 1,2,3- Triazoles.